Breaking News

Financial Results: Patheon 4Q12

December 17, 2012

CMO revenues up 18% in the quarter

Patheon

4Q Revenues: $210.0 million (flat) 

4Q Loss: $23.1 million (loss of $9.9 million in 4Q11)

YTD Revenues: $749.1 million (+7%)

YTD Loss: $106.7 million (loss of $16.4 million YTD11)

Comments: Commercial manufacturing revenues in the quarter were $172.7 million, up 18%, and for the year were $610.7 million, up 7%. Pharmaceutical Development Services revenues in the quarter were $37.5 million, up 7%, and for the year were $138.4 million, up 9%. The loss before discontinued operations was $106.4 million YTD compared to a loss of $15.8 million last year, primarily due to the asset impairment charge of $57.9 million related to closing the Swindon, UK facility.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision